Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BPYT-01
- Development stage
- Unknown
- Lead developer
- Biosyngen
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
BPYT-01 is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed by Baiji Youtang (Guangdong) Pharmaceutical Technology Co., Ltd. It is primarily indicated for the treatment of obesity and overweight, as well as type 2 diabetes mellitus. The drug functions by activating the GLP-1 receptor, which enhances glucose-dependent insulin secretion, suppresses glucagon secretion, and delays gastric emptying. These actions collectively lead to improved glycemic control and significant weight reduction through increased satiety and reduced caloric intake. BPYT-01 is currently undergoing clinical evaluation to establish its safety and efficacy profile in metabolic health.
02
Targets
Beyond the preview
Go deeper on BPYT-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BPYT-01.